Inovio Pharmaceuticals, Inc. (INO) Securities Class Action Lawsuit Update

Inovio Pharmaceuticals, Inc. (INO) Securities Class Action Lawsuit Update

• Case Name: Carlson v. Inovio Pharmaceuticals, Inc. et al.
• Case No.: 2:26-cv-00803
• Jurisdiction: U.S. District Court, Eastern District of Pennsylvania
• Filed on: February 6, 2026
• Class Period: October 10, 2023 – December 26, 2025

Introduction

Inovio Pharmaceuticals, Inc. entered the latter half of 2025 still telling a familiar story: a breakthrough DNA medicine, a rare disease with no good alternatives, and a regulatory pathway that promised speed. According to a newly filed federal securities class action, they now say the story was incomplete.

The complaint alleges that Inovio and two senior executives misled investors about the readiness of its lead product candidate, INO-3107, and the company’s ability to secure accelerated FDA approval. When the company later disclosed manufacturing issues and the FDA accepted the INO-3107 BLA for standard review while raising concerns about accelerated-approval eligibility, Inovio’s stock price fell sharply, including a 24.45% one-day decline on December 29, 2025.

“Most INO shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Inovio is a biotechnology company focused on DNA-based medicines targeting HPV-related diseases, cancer, and infectious illnesses. Its platform relies on DNA plasmids paired with a proprietary delivery device known as CELLECTRA, designed to deliver electroporation directly into cells.

At the center of the case is INO-3107, Inovio’s lead product candidate for recurrent respiratory papillomatosis (RRP), a rare and lifelong HPV-driven disease that often requires repeated surgeries. Throughout the class period, Inovio positioned INO-3107 as the asset that would transform the company from a research-stage biotech into a commercial-stage enterprise. Investors were repeatedly told that transition hinged on accelerated FDA approval and priority review.

Promises Made vs. Reality

According to the complaint, Inovio consistently told investors that FDA feedback supported accelerated approval based on Phase 1/2 data, that a Phase 3 trial would not be required prior to submission, and that the company was “laser-focused” on completing a Biologics License Application by the second half of 2024. Executives publicly described “an established path to BLA [Biologics License Application] submission under the FDA’s accelerated approval program” and emphasized manufacturing readiness for both the drug and the CELLECTRA device.

Plaintiffs allege that, behind the scenes, Inovio faced unresolved manufacturing deficiencies in the CELLECTRA device and lacked sufficient data to justify eligibility for accelerated approval or priority review. The lawsuit claims those risks were reduced to boilerplate disclosures in SEC filings, warnings about what “may” or “could” happen, rather than what was allegedly already known.

Timeline of Alleged Misconduct and Disclosures

The alleged misconduct spans more than two years. Beginning in October 2023, Inovio issued press releases and SEC filings touting FDA feedback, breakthrough therapy designation, and an accelerated approval strategy. Through 2024 and 2025, the company completed multiple equity offerings while reiterating that it remained on track for accelerated submission.

The first crack appeared on August 8, 2024, when Inovio disclosed a manufacturing issue with a component of the CELLECTRA device, pushing the BLA submission timeline back by roughly a year. Shares fell modestly the next day. “The complaint describes analyst reactions following the disclosure, including price-target changes.

The more severe reckoning arrived on December 29, 2025. Inovio revealed that the FDA had accepted the INO-3107 BLA only under a standard review and had concluded that the company failed to submit adequate information to justify accelerated approval. The stock plunged more than 24% in a single session.

Investor Harm and Market Reaction

Plaintiffs tie investor losses directly to these corrective disclosures. The August 2024 manufacturing admission triggered a smaller decline, but the December 29, 2025 disclosure was followed by a 24.45% one-day decline in Inovio’s stock price, according to public reporting cited in the complaint.

Analysts quickly reassessed the investment thesis. H.C. Wainwright described the accelerated approval pathway as “in dispute,” while Jefferies highlighted the overhang created by a standard review timeline and Inovio’s tight cash runway. Media outlets characterized the selloff as a direct response to regulatory pushback.

Litigation and Procedural Posture

The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania, seeks to represent investors who purchased Inovio securities between October 10, 2023, and December 26, 2025. It asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.

Defendants include Inovio Pharmaceuticals, CEO Jacqueline E. Shea, and CFO Peter Kies. The complaint alleges scienter based on executives’ access to internal information, their repeated assurances regarding regulatory alignment, and the company’s repeated capital raises while the stock allegedly traded at inflated levels.

Shareholder Sentiment

Retail and institutional investor sentiment deteriorated quickly after Inovio disclosed that the FDA would review the INO-3107 Biologics License Application under a standard timeline rather than the accelerated approval pathway many investors had expected. Financial media coverage tied the stock’s sharp decline to disappointment surrounding the regulatory classification and the agency’s statement that the submission did not include adequate information to support accelerated-approval eligibility.

Across social media and investor forums, the reaction frequently centered on what many described as a “moving of the goalposts” for the INO-3107 filing. Discussions on Stocktwits and Reddit communities such as r/Biotech and r/Stocks often referenced the roughly 24% one-day drop following the December 2025 disclosure, with users debating whether the setback reflected a temporary regulatory hurdle or deeper issues related to the CELLECTRA delivery device and the company’s regulatory strategy.

Commentary on financial platforms such as Seeking Alpha also shifted toward the company’s cash burn and financing outlook, with investors noting that a standard FDA review timeline, which is typically longer than priority review, could delay commercialization and increase the likelihood of additional capital raises before INO-3107 generates revenue.

Analyst Commentary

Financial analysts responded cautiously after Inovio disclosed that the FDA’s standard review timeline rather than the accelerated pathway many investors had anticipated. Financial media coverage noted that the regulatory classification materially altered expectations for the company’s lead asset and helped drive the sharp selloff in the stock.

Analyst commentary cited in market coverage reflected growing skepticism about the regulatory path forward. H.C. Wainwright analysts noted that the accelerated approval pathway was effectively “in dispute,” suggesting the FDA’s response signaled uncertainty about whether the current data package could support early approval. Other analysts highlighted that the shift to a standard review timeline extended the expected path to commercialization and increased the risk that additional regulatory hurdles could emerge during the review process.

Jefferies analysts also emphasized the financial implications of the regulatory delay. Coverage summarizing their commentary pointed to the “overhang” created by the standard review classification and warned that the company’s relatively tight cash runway could become a more significant concern if the approval timeline extends further. Financial media reports framed the selloff as a reassessment of Inovio’s risk profile, with analysts highlighting regulatory uncertainty, funding needs, and execution risk as key factors shaping the company’s near-term outlook.

SEC Filings & Risk Factors

Throughout the class period, Inovio’s Forms 10-K and 10-Q included risk disclosures about accelerated approval, manufacturing, and regulatory uncertainty. Plaintiffs allege these disclosures were generic and failed to reflect known manufacturing deficiencies and data limitations related to accelerated approval eligibility. The complaint also alleges violations of Item 303 of Regulation S-K for failing to disclose known trends and uncertainties likely to impact the business.

Conclusion: Implications for Investors

The complaint alleges that Inovio’s public statements during the class period conveyed confidence in the regulatory pathway and manufacturing readiness for its lead candidate, INO-3107. According to the lawsuit, investors later reassessed those expectations after the company disclosed manufacturing delays and the FDA accepted the therapy’s Biologics License Application under a standard review timeline rather than an accelerated pathway.

For shareholders, the case centers on whether earlier disclosures accurately reflected the regulatory and operational risks facing the program. As the litigation moves forward, the outcome will turn on whether the company’s statements and risk disclosures adequately conveyed those uncertainties to investors.

How to Join the Inovio Pharmaceuticals, Inc. (INO) Class Action

• Confirm you purchased INO shares during the relevant period
• Review eligibility details
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.